The company said it recorded a net loss of $444.6 million for the 3 months ended June 30, 2024 (basic and diluted net loss per share of $2.04), compared with net income of $203.5 million in the year-earlier period. It said it recorded a net loss of $275.1 million for the 6 months.

1. 01

   The company said it recorded a net loss of $444.6 million for the 3 months ended June 30, 2024 (basic and diluted net loss per share of $2.04), compared with net income of $203.5 million in the year-earlier period. It said it recorded a net loss of $275.1 million for the 6 months.

2. 02

   Incyte said it included $679.4 million of expense related to the in-process research and development assets acquired in the Escient acquisition in research and development expenses for the 3 and 6 months ended 2024. The company cited non-deductible costs of $710.9 million related to the Escient acquisition as the main reason its effective tax rate was higher than the U.S. statutory rate.

3. 03

   The company said the increase in OPZELURA net product revenues for Q2 2024 consisted of a volume increase of $36.4 million and a price increase of $5.1 million. Incyte said it had accrued approximately $91.1 million as of June 30, 2024 in incremental rebates that would be owed if OPZELURA were considered a line extension of JAKAFI.

4. 04

   Incyte said it had cash, cash equivalents and marketable securities of $1.4 billion as of June 30, 2024. Net cash used in operating activities was $356.8 million and net cash used in financing activities was $2.01 billion for the 6 months ended 2024, mainly due to share repurchases of $2.00 billion.

Key figures

Quarter ended June 30, 2024

Revenue

$1.0B

Operating income

−$478M

Net income

−$445M

EPS

−$2.04

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.